Back to discover
Disease
Bronchiectasis
Late-stage therapeutic developmentEmerging research
3
Publications
20
Clinical trials
2024
Latest publication
Current focus
Therapeutic developmentGenetics & risk factorsDisease mechanisms & pathology
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Regulatory2025-11-18EMA
Research2024-07-17Respiratory research
Pathophysiology and genomics of bronchiectasis.
Research2024-07-03European respiratory review : an official journal of the European Respiratory Society
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 1 regulatory approval from EMA on record.
- 5 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
- Q4 2027A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)
- Q4 2027Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
- Q3 2028A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)
- Q1 2029Phase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis
- Q4 2030Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity
Major developments
Upcoming trial readoutHigh impact
Results expected Q3 20282026-07-09
Upcoming trial readoutHigh impact
Results expected Q1 20292026-06-01
Important regulatory approvalImportant
Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.2025-11-18
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-07-09A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)Results expected Q3 2028
- 2026-06-18A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)Results expected Q4 2027
- 2026-06-01Phase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis BronchiectasisResults expected Q1 2029
- 2026-05-29Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome DiversityResults expected Q4 2030
- 2025-08-11Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesResults expected Q4 2027
Recently completed
- 2025-12-23Evaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)Completed
- 2025-11-15Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled TrialCompleted
Regulatory UpdatesViewHide
- 2025-11-18Approval — Brensocatib MonohydrateBrinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
Activity timeline9
- 2026-07-09ClinicalA Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)Results expected Q3 2028
- 2026-06-18ClinicalA Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)Results expected Q4 2027
- 2026-06-01ClinicalPhase 3 Single-arm, Open-label, Multicenter Study to Assess the Safety of HSK31858 in Participants With Non-cystic Fibrosis BronchiectasisResults expected Q1 2029
- 2026-05-29ClinicalItraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome DiversityResults expected Q4 2030
- 2025-12-23ClinicalEvaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)Completed
- 2025-12-16ClinicalA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN StudyResults posted
- 2025-11-18RegulatoryApproval — Brensocatib MonohydrateBrinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
- 2025-11-15ClinicalEfficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled TrialCompleted
- 2025-08-11ClinicalClinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesResults expected Q4 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Brensocatib Monohydrateapproved
Approval — Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in… (2025)
Clinical trials
The current development programme across all trial phases.
Clinical programme
20
6
17
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2025emaApproval — Brensocatib Monohydrate· Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20212024
Most influential
Major themes8
- Bronchiectasis3
- Arthritis, Rheumatoid1
- Genetic Predisposition to Disease1
- Genomics1
- Hypertension, Pulmonary1
- Lung1
- Lung Diseases, Interstitial1
- Pulmonary Fibrosis1
Leading journals2
- European respiratory review : an official journal of the European Respiratory Society2
- Respiratory research1
Leading researchers8
- Chalmers JD1
- Cheng LL1
- Duan JL1
- Faner R1
- Gao LF1
- Guan WJ1
- Huang PR1
- Jiang Y1
Affiliations (unnormalised)6
- Center for Interstitial Lung Diseases1
- Division of Molecular and Clinical Medicine1
- Guangzhou National Laboratory1
- Hospital Clínic1
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)1
- State Key Laboratory of Respiratory Disease1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Persistent abnormal dilatation of the bronchi.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.